News
FDA approves first gene therapy, betibeglogene autotemcel (Zynteglo), for beta-thalassemia
The one-time gene therapy represents a potential cure in which functional copies of the mutated gene are inserted into patients’ hematopoietic...
News
Annual PSA screening important for Black men
“Given that Black men are younger at diagnosis and have worse prostate cancer survival compared with White men,” more intensive screening...
News
FDA approves trastuzumab-deruxtecan for HER2-low breast cancer
Sixty percent of patients previously classified as having HER2-negative subtype are now considered HER2 low.
News
HPV vaccination with Cervarix ‘unmasks’ cervical lesions from non-vax strains
The increase wasn’t enough to offset the overall benefit of vaccination when all genotypes were considered, said the researchers.
News
Acetaminophen linked to diminished response to immunotherapy in cancer
“Commonly used medications may have a larger impact on the efficacy and toxicity of immune checkpoint blockade than historically seen with...
News
Debate: Should biologics be used for milder cases of psoriasis?
The decision to use a biologic should hinge on how badly patients and their quality of life are affected, Dr. Langley said.
News
Clearance rates higher with bimekizumab vs. secukinumab in phase 3 psoriasis study
As in past trials, oral candidiasis was an issue in patients taking bimekizumab.
News
Bimekizumab tops adalimumab for plaque psoriasis
Bimekizumab “appears more effective than current options. The big question is safety.”
News
Quicker fertility rebound in young women with breast cancer
Phase 3 results support omitting cyclophosphamide from standard chemotherapy.
News
Anthracycline-free neoadjuvant regimen safe, effective for TNBC
A taxane/platinum doublet works just as well as the standard anthracycline-containing regimen.
News
Prospects dim for Medicare drug reimbursement cuts
A proposal to lower Medicare Part B reimbursements for 50 physician-administered drugs and biologics to what drug manufacturers receive for them...